In late February, the Senate Finance Committee assembled the nation’s top pharmaceutical company executives and grilled them on why prescription drugs remain so high. AbbVie Pharmaceuticals’ CEO, Richard Gonzalez, pushed back, arguing that without a high sticker price, progress stops.
So what are the costs of doing business for American drug makers? And is true reform possible?
With The Show to talk about that was Kenneth Kaitin, director of the Tufts Center for the Study of Drug Development.
